Patents by Inventor Michimoto Kobayashi
Michimoto Kobayashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11733250Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.Type: GrantFiled: September 28, 2021Date of Patent: August 22, 2023Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Michimoto Kobayashi, Mitsuaki Sanada, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Publication number: 20220120752Abstract: The present invention provides a method for detecting biliary tract cancer by measuring the amounts of APOA2 protein variants in a test sample with anti-APOA2 antibodies, the anti-APOA2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.Type: ApplicationFiled: December 28, 2021Publication date: April 21, 2022Applicants: Toray Industries, Inc., NATIONAL CANCER CENTERInventors: Mitsuaki Sanada, Michimoto Kobayashi, Aiko Takayama, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Patent number: 11231423Abstract: The present invention provides a method for detecting biliary tract cancer by measuring the amounts of APOA2 protein variants in a test sample with anti-APOA2 antibodies, the anti-APOA2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.Type: GrantFiled: January 25, 2016Date of Patent: January 25, 2022Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Mitsuaki Sanada, Michimoto Kobayashi, Aiko Takayama, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Publication number: 20220011322Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.Type: ApplicationFiled: September 28, 2021Publication date: January 13, 2022Applicants: Toray Industries, Inc., NATIONAL CANCER CENTERInventors: Michimoto Kobayashi, Mitsuaki Sanada, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Patent number: 11162956Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.Type: GrantFiled: March 1, 2016Date of Patent: November 2, 2021Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Michimoto Kobayashi, Mitsuaki Sanada, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Publication number: 20180031574Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.Type: ApplicationFiled: March 1, 2016Publication date: February 1, 2018Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Michimoto Kobayashi, Mitsuaki Sanada, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Publication number: 20180017564Abstract: The present invention provides a method for detecting biliary tract cancer by measuring the amounts of APOA2 protein variants in a test sample with anti-APOA2 antibodies, the anti-APOA2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.Type: ApplicationFiled: January 25, 2016Publication date: January 18, 2018Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Mitsuaki Sanada, Michimoto Kobayashi, Aiko Takayama, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Publication number: 20160245815Abstract: It is intended to provide a method for detecting a pancreatic tumor (pancreatic cancer or benign pancreatic tumor) with low invasiveness to a test subject and with high detection sensitivity and accuracy. The present invention provides a method for detecting a pancreatic tumor by measuring the amounts of APOA2 protein variants in a sample of a test subject using anti-APOA2 antibodies, anti-APOA2 antibodies for use in the method, and a kit for the detection of a pancreatic tumor, comprising the antibodies.Type: ApplicationFiled: September 30, 2014Publication date: August 25, 2016Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Mitsuaki SANADA, Michimoto KOBAYASHI, Aiko TAKAYAMA, Yoshiyuki SASAJIMA, Giman JUNG, Tesshi YAMADA, Kazufumi HONDA
-
Patent number: 9127054Abstract: An object of the present invention is to realize an antibody or a fragment thereof specifically recognizing a cofilin 1 protein, and a method for detecting and testing gastrointestinal cancer with high detection performance, which comprises performing immunoassay of the cofilin 1 protein using the antibody or a fragment thereof. An immunoassay of cofilin 1 protein is characterized by measuring cofilin 1 or a fragment thereof in a sample using 2 or more types of anti-cofilin 1 monoclonal antibody or fragments thereof specifically recognizing different peptide regions in the amino acid sequence constituting the cofilin 1 protein.Type: GrantFiled: December 5, 2011Date of Patent: September 8, 2015Assignees: TORAY INDUSTRIES, INC., KYOTO UNIVERSITYInventors: Michimoto Kobayashi, Yoshinori Tanaka, Aiko Takayama, Satoko Kanamori, Giman Jung, Yoshiharu Sakai, Hiroshi Okabe
-
Patent number: 9081013Abstract: It is intended to provide a method for detecting gastric cancer, which is low invasive to a human test subject and has high detection sensitivity and accuracy. The present invention provides a method comprising measuring in vitro the amount of COTL1 protein, a variant thereof, and/or a fragment thereof in a body fluid sample derived from a human test subject, and detecting the presence or absence of gastric cancer affecting the test subject on the basis of the amount, and a kit for gastric cancer diagnosis comprising an antibody capable of specifically binding to the protein.Type: GrantFiled: March 3, 2011Date of Patent: July 14, 2015Assignees: TORAY INDUSTRIES, INC., KYOTO UNIVERSITYInventors: Yoshinori Tanaka, Satoko Kanamori, Michimoto Kobayashi, Giman Jung, Yoshiharu Sakai, Hiroshi Okabe
-
Publication number: 20140363825Abstract: This invention relates to a method for detecting or examining a cancer selected from colorectal cancer and esophageal cancer with high detection sensitivity and accuracy and with less invasiveness to a subject. Specifically, it relates to a method for examining a cancer comprising measuring in vitro a COTL1 protein in a body fluid sample from a subject and evaluating whether or not the subject suffers from the cancer based on the measured amount of the COTL1 protein. It further relates to a kit for diagnosis of a cancer selected from colorectal cancer and esophageal cancer comprising an antibody or a fragment thereof capable of specifically binding to the protein.Type: ApplicationFiled: August 28, 2012Publication date: December 11, 2014Applicants: KYOTO UNIVERSITY, TORAY INDUSTRIES, INC.Inventors: Michimoto Kobayashi, Yoshinori Tanaka, Aiko Takayama, Giman Jung, Yoshiharu Sakai, Hiroshi Okabe
-
Publication number: 20130288277Abstract: An object of the present invention is to realize an antibody or a fragment thereof specifically recognizing a cofilin 1 protein, and a method for detecting and testing gastrointestinal cancer with high detection performance, which comprises performing immunoassay of the cofilin 1 protein using the antibody or a fragment thereof. An immunoassay of cofilin 1 protein is characterized by measuring cofilin 1 or a fragment thereof in a sample using 2 or more types of anti-cofilin 1 monoclonal antibody or fragments thereof specifically recognizing different peptide regions in the amino acid sequence constituting the cofilin 1 protein.Type: ApplicationFiled: December 5, 2011Publication date: October 31, 2013Applicants: KYOTO UNIVERSITY, TORAY INDUSTRIES, INC.Inventors: Michimoto Kobayashi, Yoshinori Tanaka, Aiko Takayama, Satoko Kanamori, Giman Jung, Yoshiharu Sakai, Hiroshi Okabe
-
Publication number: 20130011865Abstract: It is intended to provide a method for detecting gastric cancer, which is low invasive to a human test subject and has high detection sensitivity and accuracy. The present invention provides a method comprising measuring in vitro the amount of Cofilin 1 protein, a variant thereof, and/or a fragment thereof in a body fluid sample derived from a human test subject, and detecting the presence or absence of gastric cancer affecting the test subject on the basis of the amount, and a kit for gastric cancer diagnosis comprising an antibody capable of specifically binding to the protein.Type: ApplicationFiled: March 3, 2011Publication date: January 10, 2013Inventors: Michimoto Kobayashi, Yoshinori Tanaka, Satoko Kanamori, Giman Jung, Yoshiharu Sakai, Hiroshi Okabe
-
Publication number: 20120329074Abstract: It is intended to provide a method for detecting gastric cancer, which is low invasive to a human test subject and has high detection sensitivity and accuracy. The present invention provides a method comprising measuring in vitro the amount of COTL1 protein, a variant thereof, and/or a fragment thereof in a body fluid sample derived from a human test subject, and detecting the presence or absence of gastric cancer affecting the test subject on the basis of the amount, and a kit for gastric cancer diagnosis comprising an antibody capable of specifically binding to the protein.Type: ApplicationFiled: March 3, 2011Publication date: December 27, 2012Inventors: Yoshinori Tanaka, Satoko Kanamori, Michimoto Kobayashi, Giman Jung, Yoshiharu Sakai, Hiroshi Okabe
-
Publication number: 20110045495Abstract: The present invention relates to a method for detection of a renal cancer, comprising measuring any one of or a plurality of polypeptides shown in SEQ ID NOS: 1-7, mutants thereof, or fragments thereof in a biological sample from a subject, and to a composition for diagnosis or detection of the renal cancer.Type: ApplicationFiled: January 16, 2009Publication date: February 24, 2011Inventors: Yoshinori Tanaka, Michimoto Kobayashi, Shiori Tomoda, Giman Jung, Osamu Ogawa, Eijiro Nakamura